中国斜视与小儿眼科杂志2017，Vol.25Issue(4)：25,后插3-后插4,3.DOI:10.3969/J.ISSN.1005-328X.2017.04.009
口服普萘洛尔治疗婴幼儿眼周高风险血管瘤的临床观察
Clinical observation of oral propranolol in the management of infants with high-risk infantile periorbital hemangiomas
摘要
Abstract
Objective To assess the clinical outcomes,efficacy,and safety of propranolol in the manage-ment of infants with high-risk infantile periorbital hemangiomas (IPHs). Mehods This retrospective study was con-ducted at Xuzhou children's hospital. The medical records of 72 infants with IPHs who were treated with systemic propranolol were reviewed. The records were reviewed for treatment response, adverse events during treatment, length of treatment, and recurrences. Results A total of 26 male and 46 female infants with a mean age of 3.2 months (range, 1 to 12 months)were treated. The mean length of treatment was 6.4 months (range, 1 to 14 months). The overall treatment response was scored as excellent in 72 patients. Adverse events were encountered during treatment in 12 patients. No patients required discontinuation of treatment because of adverse events, and there were no cases of recurrence or tumor regrowth noted during the mean follow-up period of 6 months. Con-clusions Oral propranolol at a small dose was effective and well tolerated for the management of 72 infants with high-risk IPHs. Early intervention should be considered to reduce risk of visual impairment and improve esthetic outcomes.关键词
婴幼儿/眼周血管瘤/普萘洛尔Key words
Infant/Periorbital hemangiomas/Propranolol引用本文复制引用
蔡文茜,孙莉,尹瑞瑞,陈萍,王静,郝迪,吴倩,王博鹤..口服普萘洛尔治疗婴幼儿眼周高风险血管瘤的临床观察[J].中国斜视与小儿眼科杂志,2017,25(4):25,后插3-后插4,3.基金项目
江苏省科教强卫工程资助项目(编号:QNRC2016374) （编号:QNRC2016374）
